comparemela.com

Page 4 - Corina Dutcus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, .

United statesNew zealandGregory lubinieckiCorina dutcusThomas hutsonGlobal clinical developmentInternational metastaticEisai co ltdUrologic cancer researchDatabase consortiumMerck research laboratoriesEisai europe ltdTreatment centerMerck co incUrologic oncology programStatement of merck co inc

Keytruda/Lenvima Trials Stop Due to Lack of Benefit

Two clinical trials investigating Keytruda plus Lenvima will be discontinued after the drug duo was not superior to other regimens for melanoma and colorectal cancer subsets.

Keytruda lenvimaGregory lubinieckiCorina dutcusMerck research laboratoriesGlobal clinical developmentEisai incVice presidentSkin cancerColorectal cancer

Eisai : and Merck & Co , Inc , Rahway, NJ, USA Provide Update on Phase 3 Trials of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Eisai Co., Ltd. Merck & Co., Inc., Rahway, NJ, USA . | April 7, 2023

United statesPeter dannenbaumHaruo naitoDamini chokshiCorina dutcusGregory lubinieckiJohn infantiJulie cunninghamOncology at eisai incData monitoring committeeMerck co incUnited states research laboratoriesClinical developmentEisai co ltdGlobal clinical developmentUnited states provide update

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

07.04.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple .

United statesNew zealandGregory lubinieckiCorina dutcusExchange commissionMerck co stockData monitoring committeeMerck co incEisai co ltdMerck research laboratoriesOncology at eisai incEisai europe ltdStatement of merck co incClinical developmentUnited nations sustainable development goals sdgsGlobal clinical development

Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy,. | April 7, 2023

United statesNew zealandCorina dutcusGregory lubinieckiOncology at eisai incMerck co incData monitoring committeeStatement of merck co incGlobal clinical developmentEisai incMerck research laboratoriesExchange commissionEisai europe ltdEisai co ltdClinical developmentUnited nations sustainable development goals sdgs

vimarsana © 2020. All Rights Reserved.